B
B. Zhou
Researcher at Janssen Pharmaceutica
Publications - 29
Citations - 3012
B. Zhou is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Psoriatic arthritis & Placebo. The author has an hindex of 12, co-authored 27 publications receiving 2503 citations.
Papers
More filters
Journal ArticleDOI
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Christopher E.M. Griffiths,Bruce Strober,Peter C.M. van de Kerkhof,Vincent T. Ho,Roseanne Fidelus-Gort,Newman Yeilding,Cynthia Guzzo,Yichuan Xia,B. Zhou,Shu Li,Lisa T. Dooley,Neil H. Goldstein,Alan Menter +12 more
TL;DR: The efficacy of ustekinumab at a dose of 45 or 90 mg was superior to that of high-dose etanercept over a 12-week period in patients with psoriasis.
Journal ArticleDOI
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial
C Antoni,Gerald G. Krueger,K. de Vlam,C. Birbara,A. Beutler,Cynthia Guzzo,B. Zhou,Lisa T. Dooley,Arthur Kavanaugh +8 more
TL;DR: Infliximab 5 mg/kg through 24 weeks significantly improved active PsA, including dactylitis and enthesopathy, and associated psoriasis.
Journal ArticleDOI
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study
Ronald F van Vollenhoven,Ronald F van Vollenhoven,Bevra H. Hahn,George C. Tsokos,Carrie Wagner,Peter Lipsky,Zahi Touma,Victoria P. Werth,Victoria P. Werth,R. Gordon,B. Zhou,Benjamin Hsu,Marc Chevrier,Manon Triebel,Jarrat Jordan,Shawn Rose +15 more
TL;DR: The addition of ustekinumab to standard-of-care treatment resulted in better efficacy in clinical and laboratory parameters than placebo in the treatment of active systemic lupus erythematosus and had a safety profile consistent with usteksineumab therapy in other diseases.
Journal ArticleDOI
The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year
A. Kavanaugh,C Antoni,Dafna D. Gladman,Siegfried Wassenberg,B. Zhou,A. Beutler,Gregory Keenan,G.-R. Burmester,Daniel E. Furst,M Weisman,J. R. Kalden,Josef S. Smolen,D. van der Heijde +12 more
TL;DR: Infliximab inhibits radiographic progression in patients with PsA through week 50, and the effect of infliximab (IFX) on structural damage in PsA is assessed using IMPACT trial data.
Journal ArticleDOI
Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2.
D. van der Heijde,A. Kavanaugh,Dafna D. Gladman,C Antoni,Gerald G. Krueger,Cynthia Guzzo,B. Zhou,Lisa T. Dooley,K. de Vlam,P. Geusens,C. Birbara,D. Halter,A. Beutler +12 more
TL;DR: Infliximab significantly inhibits radiographic progression in patients with PsA as early as 6 months after starting treatment, and the beneficial effect continues through 1 year of infliximab therapy.